JP2010100530A - Anti-obestic agent - Google Patents

Anti-obestic agent Download PDF

Info

Publication number
JP2010100530A
JP2010100530A JP2008270432A JP2008270432A JP2010100530A JP 2010100530 A JP2010100530 A JP 2010100530A JP 2008270432 A JP2008270432 A JP 2008270432A JP 2008270432 A JP2008270432 A JP 2008270432A JP 2010100530 A JP2010100530 A JP 2010100530A
Authority
JP
Japan
Prior art keywords
post
tea
obesity
fermented tea
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008270432A
Other languages
Japanese (ja)
Inventor
Mitsumasa Manso
三正 万倉
Yuki Hidaka
祐樹 日高
Tadamichi Sonoda
忠道 園田
Takashi Matsumoto
隆 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ikeda Shokken KK
Original Assignee
Ikeda Shokken KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ikeda Shokken KK filed Critical Ikeda Shokken KK
Priority to JP2008270432A priority Critical patent/JP2010100530A/en
Publication of JP2010100530A publication Critical patent/JP2010100530A/en
Pending legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide an anti-obestic agent which is originated from a vegetable ingredient high in safety and is excellent in physiological actions. <P>SOLUTION: There are provided the anti-obestic agent comprising a post-heating fermented tea which is obtained by adding water in an amount of 110 pts.wt. per 100 pts.wt. of the dry weight of tea originated from Camellia sinensis and then inoculating and growing a fungus in the mixture, and has superoxide dismutase activity of ≥2,000 units/g in terms of solid content, or an extract of the post-heating fermented tea; and the anti-obestic agent, wherein obesity is visceral fat obesity or subcutaneous fat obesity. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

本発明は、スーパーオキシドジスムターゼ(Superoxide Dismutase)活性(以下、SOD活性という)を有する後発酵茶又はその抽出物を含有する抗肥満剤に関する。   The present invention relates to an anti-obesity agent containing post-fermented tea having superoxide dismutase activity (hereinafter referred to as SOD activity) or an extract thereof.

糖尿病などの生活習慣病は、内臓に脂肪が蓄積した内臓脂肪型肥満が原因で引き起こされることが多く、内臓脂肪型肥満に加えて、高血糖、高血圧、脂質異常のうちいずれか2つ以上をあわせもった状態を、メタボリックシンドロームとされている。メタボリックシンドロームの多くは、放置しておくと動脈硬化を進行させ、ひいては心臓病や脳卒中につながる。それゆえ、メタボリックシンドロームを予防する事は重要である。
メタボリックシンドロームは、体重減量、とくに内臓脂肪減量によりその予防が期待できるといわれており、抗肥満剤や抗肥満効果を有するものが求められている。
Lifestyle-related diseases such as diabetes are often caused by visceral fat-type obesity in which fat has accumulated in the viscera. In addition to visceral fat-type obesity, any two or more of hyperglycemia, hypertension, and lipid abnormalities The combined state is regarded as metabolic syndrome. Many of the metabolic syndrome can cause arteriosclerosis if left untreated, leading to heart disease and stroke. Therefore, it is important to prevent metabolic syndrome.
Metabolic syndrome is said to be able to be prevented by weight loss, especially visceral fat loss, and anti-obesity agents and those having anti-obesity effects are required.

茶による抗肥満や脂肪吸収抑制については、例えば、後発酵茶であるプーアル茶抽出成分またはジャスミン茶抽出成分を用いたダイエット後のリバウンド抑制効果を有する茶飲料及び脂肪吸収抑制剤(特許文献1)が知られている。また、茶に起源を発するリパーゼ阻害活性を有する新規ポリフェノール化合物を含み、食事由来の脂肪の吸収を抑制し、血中中性脂肪の上昇を抑える飲食料を提供する(特許文献2)ものが知られている。   As for anti-obesity and fat absorption suppression by tea, for example, tea drink and fat absorption inhibitor having a rebound suppression effect after dieting using puer tea extract component or jasmine tea extract component which is post-fermented tea (Patent Document 1) It has been known. In addition, a novel polyphenol compound having a lipase inhibitory activity originating in tea is provided, and a food and drink that suppresses the absorption of dietary fat and suppresses the increase of blood neutral fat is known (Patent Document 2). It has been.

エネルギー消費の自立的調節に関与する物質として、UCP(Uncoupling Protein:ミトコンドリア脱共役タンパク質)が着目されており、UCPはミトコンドリア内膜での酸化的リン酸化反応を脱共役させ、エネルギーを熱として散逸する機能を持っている。具体的には、多食しても肥満しない動物はUCP1(褐色脂肪組織中のUCP)が多い、人為的にUCP1の発現を低下させたマウスは肥満し、高発現させたマウスはやせる、などの事実が知られている(非特許文献1)。それゆえ、UCPを高発現させれば抗肥満効果が期待できる。   As a substance involved in the self-regulation of energy consumption, UCP (Uncoupling Protein) has attracted attention. UCP uncouples oxidative phosphorylation in the inner mitochondrial membrane and dissipates energy as heat. Have the ability to Specifically, animals that do not become obese even if they eat a lot have more UCP1 (UCP in brown adipose tissue), mice that have artificially reduced the expression of UCP1 are obese, and mice that are highly expressed can lose weight, etc. The fact is known (Non-Patent Document 1). Therefore, anti-obesity effect can be expected if UCP is highly expressed.

特開2005−278478号公報JP 2005-278478 A 特開2006−001909号公報JP 2006-001909 A 斎藤昌之、「第124回日本医学会シンポジウム記録集 肥満の科学」、日本医学会、p.62−70、2003年Masayuki Saito, "The 124th Symposium of the Japan Medical Association Symposium on Obesity", Japan Medical Association, p. 62-70, 2003

茶による抗肥満や脂肪吸収抑制については、プーアル茶に代表される従来の後発酵茶の抗肥満効果は十分でなく、より強い抗肥満効果を有する植物由来の成分が望まれていた。
従って、本発明は、安全性が高い植物成分由来であって、より薬理作用の優れた抗肥満剤を提供することにある。
Regarding anti-obesity and fat absorption suppression by tea, the anti-obesity effect of conventional post-fermented tea represented by puer tea is not sufficient, and a plant-derived component having a stronger anti-obesity effect has been desired.
Accordingly, an object of the present invention is to provide an anti-obesity agent that is derived from a plant component with high safety and has a more excellent pharmacological action.

本発明者らは、後発酵茶に着目して種々検討し、ある特定量の水分を茶に含浸させ、糸状菌を接種して生育させたところ、SOD活性が著しく高い後発酵茶が得られた。そして、当該SOD活性の高い後発酵茶を用いて肥満モデルにおける肥満抑制効果を検討したところ、この後発酵茶を投与すれば、強力な肥満抑制効果が得られることを見出し、本発明を完成した。また、この後発酵茶を投与すれば、UCPの発現を促進することを見出した。   The present inventors have made various studies focusing on post-fermented tea, impregnated tea with a certain amount of water, inoculated with filamentous fungi, and grown to obtain post-fermented tea with extremely high SOD activity. It was. And when the obesity suppression effect in an obesity model was investigated using the said post-fermented tea with the said high SOD activity, if this post-fermentation tea was administered, it discovered that a strong obesity suppression effect was acquired and completed this invention. . Further, it was found that if fermented tea is administered thereafter, the expression of UCP is promoted.

すなわち、本発明は、Camellia sinensis種由来の茶に、茶乾燥重量100重量部に対して110重量部以上の水を加え、糸状菌を接種して生育せしめることにより得られる、スーパーオキシドジスムターゼ(Superoxide Dismut
ase)活性を固形分換算で2,000units/g以上を有する後発酵茶又はその抽出物を含有する抗肥満剤を提供するものである。また、本発明は、肥満が、内臓脂肪型肥満又は皮下脂肪型肥満である前記記載の抗肥満剤を提供するものである。さらに、本発明は、UCPの発現を促進するものである前記記載の抗肥満剤を提供するものである。
That is, the present invention provides a superoxide dismutase (Superoxide) obtained by adding 110 parts by weight or more of water to tea derived from Camellia sinensis, and inoculating and growing a fungus. Dismut
as) An anti-obesity agent containing post-fermented tea having an activity of 2,000 units / g or more in terms of solid content or an extract thereof. The present invention also provides the anti-obesity agent described above, wherein the obesity is visceral fat type obesity or subcutaneous fat type obesity. Furthermore, the present invention provides the above-mentioned anti-obesity agent that promotes the expression of UCP.

本発明の後発酵茶又はその抽出物の抗肥満効果は強力であり、特に、肥満が内臓脂肪型肥満又は皮下脂肪型肥満に有効である。また、本発明の後発酵茶又はその抽出物はUCPの発現を促進し、抗肥満効果を示すものである。また、本発明で用いる後発酵茶又はその抽出物は安全性が高く、長期間飲用又は服用が可能であることから、特に肥満への移行の防止又は治療に有用である。   The anti-obesity effect of the post-fermented tea or its extract of the present invention is strong, and obesity is particularly effective for visceral fat type obesity or subcutaneous fat type obesity. Further, the post-fermented tea or the extract thereof of the present invention promotes the expression of UCP and exhibits an anti-obesity effect. In addition, post-fermented tea or an extract thereof used in the present invention is highly safe and can be drunk or taken for a long period of time. Therefore, it is particularly useful for preventing or treating the transition to obesity.

本発明に用いる後発酵茶の原料としての茶は、Camellia sinensis種であれば、特に品種等には限定されない。また、収穫直後の生茶葉、青殺後の茶葉、粗揉後の茶葉、揉捻後の茶葉、中揉後の茶葉、精揉後の茶葉、荒茶等の緑茶であっても、茶茎、茶花及びこれらの粉末品等の加工品等であっても、さらに半発酵茶、完全発酵茶も使用可能であり、原料となる茶は後発酵茶の用途により、適宜選択可能である。このうち、不発酵茶を用いることが、高いSOD活性を有する後発酵茶を得る点から好ましい。   If the tea as a raw material of post-fermentation tea used for this invention is a Camellia sinensis seed | species, it will not be specifically limited to a kind | species etc. In addition, fresh tea leaves immediately after harvesting, tea leaves after killing blue, tea leaves after rough culm, tea leaves after twisting, tea leaves after midsummer, tea leaves after brewing, green tea such as rough tea, Semi-fermented tea and completely fermented tea can also be used for tea flowers and processed products such as these powder products, and the raw tea can be appropriately selected depending on the use of post-fermented tea. Among these, it is preferable to use non-fermented tea from the viewpoint of obtaining post-fermented tea having high SOD activity.

これらの茶の発酵に用いられる微生物は、高いSOD活性を有する後発酵茶を得る点から糸状菌であるのが好ましい。糸状菌としては、醸造食品や発酵食品等の食品に使用可能な糸状菌の中から選抜することが可能である。例えば、Aspergillus属、Eurotium属、Rhizopus属等を使用することができ、より好ましくはAspergillus oryzae、Aspergillus niger、Eurotium cristatum、Rhizopus oligosporusが挙げられ、さらには該糸状菌から誘導される変異株であっても使用することができる。これらを単独で若しくはそれらを組合せて使用してもよい。これらの菌株は、IFO、IAM、ATCC、NRRC等の菌株分譲機関、日本醸造協会や市販の種菌株販売会社等から入手することができる。   The microorganism used for fermentation of these teas is preferably a filamentous fungus from the viewpoint of obtaining post-fermented tea having high SOD activity. As the filamentous fungus, it is possible to select from filamentous fungi that can be used for foods such as brewed foods and fermented foods. For example, Aspergillus genus, Eurotium genus, Rhizopus genus and the like can be used, more preferably Aspergillus oryzae, Aspergillus niger, Eurotium cristatum, Rhizopus oligosporus, and a strain that is derived from the strain that is derived from the filamentous fungus. Can also be used. These may be used alone or in combination. These strains can be obtained from strain distribution agencies such as IFO, IAM, ATCC, and NRRC, the Japan Brewing Association, and commercial seed strain sales companies.

本発明に用いる後発酵茶の製法においては、Camellia sinensis種由来の茶に、茶乾燥重量100重量部に対して110重量部以上、好ましくは150重量部以上、より好ましくは200重量部以上、最適には300〜400重量部の水を加える。ここでの水分量の調整は原料となる茶に、水を加え、馴染ませ、糸状菌が生育できる条件にすることを意味する。例えば、荒茶を使用した場合、該荒茶はすでに約3〜5重量%の水分を既に含んでおり、加える水分量は、茶が含んでいる水分を考慮して調整する必要がある。また、生茶葉のように水分を70〜80重量%含んでいるものについては、加水しなくても良い。上記の水分含量は、培養・発酵に用いる糸状菌が繁殖又は発酵可能な量であり、かつ本発明の高いSOD活性を有する後発酵茶を得るために重要である。該糸状菌を優先的に繁殖させることで、雑菌汚染をより防止することができる。該水分調整後に、殺菌工程を加えることが好ましい。該殺菌条件は、例えば、80〜100℃で30〜60分間、あるいは100〜121℃で15〜30分間等の条件で加熱殺菌を行うことが挙げられる。該殺菌後は、冷却し、該茶を殺菌済み培養・発酵槽に移し、下記の植菌工程を行う。なお、該殺菌工程は、茶の水分量が変化しないように密閉系で行うのが好ましい。   In the method for producing post-fermented tea used in the present invention, tea derived from Camellia sinensis is 110 parts by weight or more, preferably 150 parts by weight or more, more preferably 200 parts by weight or more, optimal for 100 parts by weight of tea dry weight. Add 300-400 parts by weight of water. The adjustment of the amount of water here means that water is added to tea used as a raw material so as to adjust to a condition that allows filamentous fungi to grow. For example, when crude tea is used, the crude tea already contains about 3 to 5% by weight of moisture, and the amount of moisture to be added needs to be adjusted in consideration of the moisture contained in the tea. Moreover, what contains 70 to 80 weight% of water | moisture content like fresh tea leaves does not need to be hydrated. The water content is important for obtaining the post-fermented tea having a high SOD activity according to the present invention, which is an amount capable of propagating or fermenting the filamentous fungi used for culture and fermentation. By preferentially propagating the filamentous fungus, contamination with various bacteria can be further prevented. It is preferable to add a sterilization step after the moisture adjustment. Examples of the sterilization conditions include heat sterilization at 80 to 100 ° C. for 30 to 60 minutes, or at 100 to 121 ° C. for 15 to 30 minutes. After the sterilization, the mixture is cooled, the tea is transferred to a sterilized culture / fermentor, and the following inoculation process is performed. The sterilization step is preferably performed in a closed system so that the moisture content of tea does not change.

水分含量を調整した茶に、糸状菌を接種し、一般に20〜40℃で3〜30日間、好ましくは25〜37℃で3〜7日間培養・発酵する。ここで培養・発酵方法は、通常用いられる方法であれば、液体培養・発酵法、固体培養・発酵法等いずれの方法でも良い。次いで、殺菌工程を加えることが好ましい。該殺菌条件は、例えば、80〜100℃で30〜60分間、あるいは100〜121℃で15〜30分間等の条件で加熱殺菌を行うこと、又は、80〜120℃で加熱乾燥し該糸状菌を殺菌するとともに、水分含量を10重量%以下、好ましくは5重量%以下にする。これにより、本発明のSOD活性の高い後発酵茶が製造される。   The tea whose moisture content has been adjusted is inoculated with filamentous fungi and is generally cultured and fermented at 20 to 40 ° C. for 3 to 30 days, preferably at 25 to 37 ° C. for 3 to 7 days. Here, the culture / fermentation method may be any method such as liquid culture / fermentation method or solid culture / fermentation method as long as it is a commonly used method. Then, it is preferable to add a sterilization process. The sterilization conditions include, for example, heat sterilization at 80 to 100 ° C. for 30 to 60 minutes, or 100 to 121 ° C. for 15 to 30 minutes, or heat drying at 80 to 120 ° C. Is sterilized, and the water content is 10% by weight or less, preferably 5% by weight or less. Thereby, the post-fermented tea with high SOD activity of the present invention is produced.

本発明の後発酵茶は、そのままの形態でも利用可能であるが、加熱、乾熱、マイクロ波等で殺菌を行い、さらに粉砕後、粉末、ペーストの形で、あるいは溶媒を用いて抽出し、後発酵茶抽出物として利用できる。さらに、当該後発酵茶抽出物を、スプレードライヤー、ドラムドライヤー、フリーズドライヤー、エアードライヤー等を用いて乾燥し、粉末化を行うことで、後発酵茶抽出物末とすることができる。また、必要に応じて造粒機等を用いて顆粒品とすることができる。   The post-fermented tea of the present invention can be used as it is, but is sterilized by heating, dry heat, microwave, etc., and further pulverized, extracted in the form of powder, paste, or using a solvent, It can be used as a post-fermented tea extract. Furthermore, the post-fermented tea extract can be made into a post-fermented tea extract powder by drying and pulverizing the post-fermented tea extract using a spray dryer, drum dryer, freeze dryer, air dryer or the like. Moreover, it can be set as a granule using a granulator etc. as needed.

上記抽出の際に用いる溶媒としては、水又は炭素数1〜6のアルコール類若しくはグリコール類を単独で若しくはこれら溶媒の2つ以上の組合せが使用でき、例えば水、エタノール、含水エタノール、1,3―ブチレングリコール、含水1,3−ブチレングリコール等が挙げられる。好ましくは含水エタノール若しくは含水1,3−ブチレングリコール、より好ましくは水とエタノールの5〜95:95〜5の混合物(v/v)、水と1,3−ブチレングリコールの5〜95:95〜5の混合物(v/v)が使用できる。
抽出条件としては、約20〜70℃で0.1〜5時間抽出し、ろ過を行い、得られたろ液を80〜95℃で30分間の条件で加熱処理を行い冷却することが好ましい。
上記抽出物は、適宜、不活性な不純物を除去するため、例えば液々分液、固液分液、濾過膜、活性炭、吸着樹脂、イオン交換樹脂等の公知の分離・精製方法によって、さらに精製してもよい。具体的には、抽出物末を上記抽出溶媒を用いて再度抽出することが挙げられる。
As the solvent used in the above extraction, water, alcohols having 1 to 6 carbon atoms or glycols can be used alone, or a combination of two or more of these solvents can be used. For example, water, ethanol, hydrous ethanol, 1, 3 -Butylene glycol, hydrous 1,3-butylene glycol, etc. are mentioned. Preferably water-containing ethanol or water-containing 1,3-butylene glycol, more preferably a mixture of water and ethanol 5 to 95: 95-5 (v / v), water and 1,3-butylene glycol 5 to 95:95 A mixture of 5 (v / v) can be used.
As extraction conditions, it is preferable to extract at about 20 to 70 ° C. for 0.1 to 5 hours, perform filtration, and cool the obtained filtrate by heating at 80 to 95 ° C. for 30 minutes.
The above extract is further purified by a known separation / purification method such as liquid-liquid separation, solid-liquid separation, filtration membrane, activated carbon, adsorption resin, ion exchange resin, etc., in order to remove inert impurities as appropriate. May be. Specifically, the extract powder may be extracted again using the extraction solvent.

上記の製造方法により得られた後発酵茶又はその抽出物は、抗酸化活性の一つの指標であるSOD活性を、後発酵茶固形分1g当り2,000units以上、好ましくは8,000units以上、より好ましくは9,000units以上、さらに好ましくは9,000〜500,000units有する。例えば、原料としての茶に緑茶を、Aspergillus oryzaeを用いて本発明の製造方法にて製造した後発酵茶は、SOD活性を、後発酵茶固形分1g当り9,000units以上を有している。   The post-fermented tea or extract thereof obtained by the above production method has an SOD activity that is one index of the antioxidant activity of 2,000 units or more, preferably 8,000 units or more, per 1 g of post-fermented tea solid content. Preferably, it has 9,000 units or more, more preferably 9,000 to 500,000 units. For example, post-fermented tea produced by the production method of the present invention using Aspergillus oryzae as a raw material tea has SOD activity of 9,000 units or more per 1 g of post-fermented tea solid content.

高いSOD活性を有する上記の後発酵茶又はその抽出物は、後記実施例に示すように、肥満モデルに対して優れた抗肥満効果を有する。具体的には、肥満の指標である体重推移、内臓脂肪量、レプチン値、アディポネクチン値等、これらの値を顕著に改善させた。さらに、高いSOD活性を有する上記の後発酵茶又はその抽出物は、UCPの発現を促進することを示し、特にUCP1の発現を促進することを示した。従って、前記後発酵茶又はその抽出物は、肥満の予防治療剤として有用である。   The post-fermented tea having high SOD activity or an extract thereof has an excellent anti-obesity effect on an obesity model, as shown in Examples below. Specifically, these values such as body weight transition, visceral fat mass, leptin level, adiponectin level and the like, which are indicators of obesity, were significantly improved. Furthermore, the post-fermented tea or its extract having high SOD activity has been shown to promote the expression of UCP, and in particular, to promote the expression of UCP1. Therefore, the post-fermented tea or its extract is useful as a prophylactic and therapeutic agent for obesity.

本発明の抗肥満剤は、医薬として、また特定保健用食品、機能性食品等として使用することができる。これらの医薬の投与形態としては、経口、注射、外用等が挙げられるが、経口投与形態が好ましい。経口用医薬及び食品の形態としては、アンプル、カプセル、丸剤、錠剤、粉末、顆粒、固形、液剤、ゲル、気泡等の他、各種食品中に配合することもできる。これらの組成物の調製にあたっては、賦形剤、結合剤、滑沢剤等を適宜配合することができる。これらの医薬及び食品への前記後発酵茶又はその抽出物の配合量は、固形分(乾燥重量)換算で0.0001〜20重量%、0.01〜10重量%が好ましく、特に0.01〜5重量%が好ましい。   The anti-obesity agent of the present invention can be used as a pharmaceutical, food for specified health use, functional food and the like. Examples of the administration form of these drugs include oral, injection, and external use, and the oral administration form is preferred. As forms of oral medicines and foods, in addition to ampoules, capsules, pills, tablets, powders, granules, solids, liquids, gels, bubbles, etc., they can be blended in various foods. In preparing these compositions, excipients, binders, lubricants, and the like can be appropriately blended. The blending amount of the post-fermented tea or the extract thereof in these medicines and foods is preferably 0.0001 to 20% by weight, particularly 0.01 to 10% by weight, particularly 0.01% in terms of solid content (dry weight). ~ 5 wt% is preferred.

本発明の抗肥満剤の投与量は、特に制限されないが、成人1日あたり後発酵茶又はその抽出物の固形分(乾燥重量)として、10〜5,000mg、さらに50〜1,000mg、特に100〜500mgが好ましく、これらの量は1回又は数回に分けて投与してもよい。   The dosage of the anti-obesity agent of the present invention is not particularly limited, but is 10 to 5,000 mg, more preferably 50 to 1,000 mg, particularly as solid content (dry weight) of post-fermented tea or an extract per day per adult. 100 to 500 mg is preferable, and these amounts may be administered once or divided into several times.

以下、実施例を示して本発明をさらに詳細かつ具体的に説明するが、本発明は以下の例によって限定されるものではない。   Hereinafter, the present invention will be described in more detail and specifically with reference to examples, but the present invention is not limited to the following examples.

[参考例1]
緑茶(荒茶)500gを100重量部としてそれぞれ0重量部、50重量部、70重量部、80重量部、100重量部、200重量部、300重量部、350重量部、400重量部、500重量部、700重量部の水を加え、混合後、密閉系で、80℃で60分間加熱殺菌を行った。30℃まで冷却後、該緑茶葉を、予め殺菌済みの培養・発酵槽に移し、厚み5cmになるように堆積し、Aspergillus oryzae IFO5238を植菌した。植菌後、30℃で7日間培養した後、乾燥させ、後発酵茶を得た。該後発酵茶に5,000mLの50%(体積/体積)エタノールを添加し、撹拌抽出を行った。ろ過により固液分離を行い、得られたろ液を固形分30%(重量/体積)まで濃縮し、80℃で30分間加熱処理を行い冷却して、後発酵茶抽出物を得た。該後発酵茶抽出物に関して、SOD Assay Kit−WST(同仁化学社製)を用いてSOD活性を測定し、後発酵茶固形分当たりに換算した。結果を表1に示す。
[Reference Example 1]
0, 50, 70, 80, 100, 200, 300, 350, 400, and 500 parts by weight of 500 g of green tea (raw tea). And 700 parts by weight of water were added and mixed, and then heat-sterilized at 80 ° C. for 60 minutes in a closed system. After cooling to 30 ° C., the green tea leaves were transferred to a previously sterilized culture / fermentor, deposited to a thickness of 5 cm, and inoculated with Aspergillus oryzae IFO5238. After inoculation, the cells were cultured at 30 ° C. for 7 days and then dried to obtain post-fermented tea. After that, 5,000 mL of 50% (volume / volume) ethanol was added to the fermented tea, followed by extraction with stirring. Solid-liquid separation was performed by filtration, and the obtained filtrate was concentrated to a solid content of 30% (weight / volume), heated at 80 ° C. for 30 minutes and cooled to obtain a post-fermented tea extract. With respect to the post-fermented tea extract, SOD activity was measured using SOD Assay Kit-WST (manufactured by Dojin Chemical Co., Ltd.) and converted to the amount of post-fermented tea solids. The results are shown in Table 1.

SOD活性の測定は以下の通り行った。まず、試料となる後発酵茶抽出物を蒸留水で希釈し、0.075mg/mL、0.0375mg/mL、0.0075mg/mL、及び0.00375mg/mLになるようにサンプル溶液を調製した。このサンプル溶液を96well プレートの各wellに20μLずつ分注した。次に、SOD Assay Kit−WSTに同封されているTechnical Informationに従い調製したWST working solutionを200μLずつ加えよく混合した。さらに、SOD Assay Kit−WSTに付属のTechnical Informationに従い調整したEnzyme working solutionを20μLずつマルチチャンネルピペットにて加え、プレートリーダー中で37℃、20分間インキュベートし、450nmの波長で吸光度を測定した。なお、各々にはEnzyme working solutionの代わりに付属のDilution bufferを用いたブランクを設けた。さらに、サンプル溶液の代わりに蒸留水を用いたコントロール及びそのブランクを設けた。測定した吸光度から、「スーパーオキシド」と「WST−1」から「WST−1 formazan」が生成される反応の阻害率を求め、さらにサンプルのIC50値(単位:g/mL)を算出した。
また、サンプル溶液の代わりにSOD標準品を用い、SOD濃度と阻害率の関数にて検量線を作成した。作成した検量線から、SODのIC50値(単位:units/mL)を算出した。
上記の「サンプルのIC50値」及び「SODのIC50値」からサンプルのSOD活性を算出した。計算式は以下の通りである。
(サンプルのSOD活性 単位:units/g)=(SODのIC50値)÷(サンプルのIC50値)
The measurement of SOD activity was performed as follows. First, a post-fermented tea extract serving as a sample was diluted with distilled water, and sample solutions were prepared to be 0.075 mg / mL, 0.0375 mg / mL, 0.0075 mg / mL, and 0.00375 mg / mL. . 20 μL of this sample solution was dispensed into each well of a 96-well plate. Next, 200 μL of WST working solution prepared in accordance with Technical Information enclosed in SOD Assay Kit-WST was added and mixed well. Furthermore, 20 μL of Enzyme working solution adjusted according to Technical Information attached to SOD Assay Kit-WST was added by 20 μL each with a multi-channel pipette, incubated at 37 ° C. for 20 minutes in a plate reader, and the absorbance was measured at a wavelength of 450 nm. In addition, each was provided with a blank using the attached Dilution buffer instead of the Enzyme working solution. Further, a control using distilled water instead of the sample solution and its blank were provided. From the measured absorbance, the inhibition rate of the reaction in which “WST-1 formatzan” was produced from “superoxide” and “WST-1” was determined, and the IC 50 value (unit: g / mL) of the sample was calculated.
In addition, a standard curve was prepared using a function of SOD concentration and inhibition rate, using an SOD standard product instead of the sample solution. The IC 50 value of SOD (unit: units / mL) was calculated from the prepared calibration curve.
The SOD activity of the sample was calculated from the above “IC 50 value of sample” and “IC 50 value of SOD”. The calculation formula is as follows.
(SOD activity of sample unit: units / g) = (IC 50 value of SOD) ÷ (IC 50 value of sample)

Figure 2010100530
Figure 2010100530

表1より、水添加量200〜500重量部の範囲で高いSOD活性を、300〜400重量部でより高いSOD活性を示すことがわかる。   From Table 1, it can be seen that a high SOD activity is exhibited in the range of 200 to 500 parts by weight of water addition, and a higher SOD activity is exhibited in the range of 300 to 400 parts by weight.

また、得られた後発酵茶抽出物を皮膚に塗布したところほとんど刺激性がなかった。また、味も渋味が低く良好であった。   Moreover, when the obtained fermented tea extract was applied to the skin, there was almost no irritation. Also, the taste was good with low astringency.

また、同様の方法で、従来から飲用されている後発酵茶のSOD活性を測定した結果を表2に示す。   Moreover, the result of having measured the SOD activity of the post-fermented tea conventionally drunk by the same method is shown in Table 2.

Figure 2010100530
Figure 2010100530

表2より、本発明の後発酵茶が、従来の後発酵茶に比べて高いSOD活性を有することがわかる。   From Table 2, it can be seen that the post-fermented tea of the present invention has a higher SOD activity than the conventional post-fermented tea.

[参考例2]
緑茶(荒茶)500gに、1,750mLの水を加え混合後、密閉系で、80℃で60分間加熱殺菌を行った。30℃まで冷却後、該緑茶を、予め殺菌済みの培養・発酵槽に移し、厚み4cmになるように堆積し、Aspergillus oryzae IFO5238を植菌した。植菌後、30℃で7日間培養・発酵させた。培養・発酵完了後、送風乾燥機にて乾燥させ、本発明の後発酵茶486gを得た。次いで、該後発酵茶に、5,000mLの水を添加し、50℃で1時間、撹拌抽出を行った。ろ過により固液分離を行い、得られたろ液を固形分30%まで濃縮し、80℃で30分間加熱処理を行い冷却して、後発酵茶水抽出物を得た。得られた後発酵茶水抽出物をフリーズドライヤーにて乾燥することで、後発酵茶水抽出物末を得た(108g)。得られた後発酵茶水抽出物末に関して、SOD Assay Kit−WSTを用いSOD活性を測定した結果、後発酵茶固形分1g当たり、20,062units(後発酵茶水抽出物末1g当たり80,238units)であった。得られた抽出物末は、渋味もなく、苦味もなく、皮膚刺激性もなく、良好であった。
[Reference Example 2]
1,750 mL of water was added to 500 g of green tea (raw tea) and mixed, and then heat-sterilized at 80 ° C. for 60 minutes in a closed system. After cooling to 30 ° C., the green tea was transferred to a previously sterilized culture / fermentor, deposited to a thickness of 4 cm, and Aspergillus oryzae IFO5238 was inoculated. After inoculation, the cells were cultured and fermented at 30 ° C. for 7 days. After completion of the culture and fermentation, the mixture was dried with a blow dryer to obtain 486 g of post-fermented tea of the present invention. Next, 5,000 mL of water was added to the post-fermented tea, and stirring extraction was performed at 50 ° C. for 1 hour. Solid-liquid separation was performed by filtration, and the obtained filtrate was concentrated to a solid content of 30%, followed by heat treatment at 80 ° C. for 30 minutes and cooling to obtain a post-fermented tea water extract. The obtained post-fermented tea water extract was dried with a freeze dryer to obtain a post-fermented tea water extract powder (108 g). Regarding the obtained post-fermented tea water extract powder, the SOD activity was measured using SOD Assay Kit-WST. there were. The obtained extract powder was good with no astringency, no bitterness and no skin irritation.

[実施例1]
下記の実験により本発明である後発酵茶水抽出物のラットによる肥満抑制効果を評価した。
[Example 1]
The following experiment evaluated the obesity suppression effect by the rat of the post-fermented tea water extract which is this invention.

(1)実験方法
実験動物として、8週齢Wistar系雄性ラット(体重188−226g/匹)を用いた。
動物はポリプロピレン不透明ケージ(W220×L320×H135)内で2〜3匹ずつ飼育した。飼育室は、湿度40〜50%、室温20〜25℃に維持し、12時間の明暗サイクル(点灯;AM8:00、消灯;PM8:00)に設定した。
(1) Experimental method As experimental animals, 8-week-old Wistar male rats (body weight 188-226 g / animal) were used.
Two to three animals were kept in polypropylene opaque cages (W220 × L320 × H135). The breeding room was maintained at a humidity of 40 to 50% and a room temperature of 20 to 25 ° C., and was set to a 12 hour light / dark cycle (lit; AM 8:00, extinguished; PM 8:00).

本実験は、ラットを各群6匹の4群に分け、表3の飼料、飲水を自由摂取させ、17週間飼育した。普通食投与群を(i)群とし、他の(ii)群、(iii)群、及び(iv)群には肥満を引き起こすために、普通食100重量部にラード30重量部を混合した高脂肪食を与えた。(ii)群を高脂肪食投与の対照とし、(iii)群と(iv)群とを高脂肪食投与における後発酵茶抽出物の飲水投与による評価群とした。飲水として、(i)群と(ii)群とには水道水を与え、(iii)群には、後発酵茶抽出物(参考例2で得た物)を1日当たり該ラット体重1kg換算で200mg投与となるように含有させた水道水を与え、(iv)群には、後発酵茶抽出物(参考例2で得た物)を1日当たり該ラット体重1kg換算で600mg投与となるように含有させた水道水を与えた。
各群の動物の体重、摂餌量、及び飲水量を毎日測定した。投与期間終了後、犠牲死させ、該ラットの内臓脂肪の重量測定、血液の生化学的検査、及びUCPの発現を調べた。
In this experiment, rats were divided into 4 groups of 6 animals, and the food and drinking water shown in Table 3 were freely fed and bred for 17 weeks. In order to cause obesity in the group (i), the other group (ii), (iii), and (iv) were mixed with 30 parts by weight of lard to 100 parts by weight of ordinary food. I gave a fat diet. The group (ii) was used as a control for high fat diet administration, and the groups (iii) and (iv) were used as evaluation groups for drinking the post-fermented tea extract in high fat diet administration. As drinking water, tap water is given to the groups (i) and (ii), and the post-fermented tea extract (obtained in Reference Example 2) is given to the group (iii) in terms of 1 kg of the rat body weight per day. Tap water containing 200 mg was given, and (iv) group was given 600 mg of post-fermented tea extract (obtained in Reference Example 2) in terms of 1 kg of rat weight per day. The contained tap water was given.
The body weight, food intake, and water consumption of each group of animals were measured daily. At the end of the administration period, the rats were sacrificed and the rats were weighed for visceral fat, examined for blood biochemistry, and examined for UCP expression.

上記普通食としては、オリエンタル酵母工業製の実験動物用飼料MFを用いた。その組成は、100g中、水分7.7g、粗蛋白質23.6g、粗脂質5.3g、粗灰分6.1g、粗繊維2.9g、可溶性無窒素物54.4gであった。
As the above-mentioned normal food, feed MF for laboratory animals manufactured by Oriental Yeast Co., Ltd. was used. The composition was 7.7 g of water, 23.6 g of crude protein, 5.3 g of crude lipid, 6.1 g of crude ash, 2.9 g of crude fiber, and 54.4 g of soluble nitrogen-free product in 100 g.

Figure 2010100530
Figure 2010100530

全ての結果は、統計学的処理を行い、平均値±標準誤差で示した。得られたデータは一元配置分散分析(analysis of variance、ANOVA)後、Turkeyの多重比較検定法を用いて統計学的処理を行った。2群間の比較にはStudents t−testを用い、危険率5%以下を優位差有りと判定した。   All results were statistically processed and expressed as mean ± standard error. The obtained data were subjected to statistical processing using one-way analysis of variance (ANOVA) followed by Turkey's multiple comparison test. For comparison between the two groups, Students t-test was used, and a risk rate of 5% or less was determined to be superior.

(2)実験結果
各群の動物の体重、摂餌量、及び飲水量を毎日測定し、毎週の平均とした結果を図1〜図3に示す。また、投与期間終了後、犠牲死させ、該ラットの内臓脂肪の重量測定、血液の生化学的検査、及びUCPの発現を調べた結果を以下に示す。
(2) Experimental results The body weight, food intake, and water consumption of each group of animals were measured daily, and the weekly average results are shown in FIGS. In addition, after the administration period, sacrifice was performed, and the results of measurement of visceral fat weight, blood biochemical examination, and UCP expression in the rat are shown below.

図1において、飼育期間中の体重については、後発酵茶水抽出物投与の(iii)群と(iv)群は、高脂肪食投与の対照である(ii)群より小さな値を示し、体重増加を抑制することを示した。特に、(iv)群は、(ii)群と比較し、17週目には危険率1%で有意差がある事を示した。後発酵茶水抽出物は、体重増加抑制に優れ、顕著な肥満抑制効果を示した。   In FIG. 1, regarding the body weight during the breeding period, the (iii) group and (iv) group administered with the post-fermented tea water extract showed a smaller value than the group (ii) which was the high fat diet administered control, and the body weight increased. It was shown to suppress. In particular, the (iv) group showed a significant difference with a risk rate of 1% at the 17th week compared to the (ii) group. The post-fermented tea water extract was excellent in suppressing weight gain and showed a remarkable obesity-inhibiting effect.

図2及び図3では、飼育期間中での各群の平均摂餌量及び平均飲水量については、有意な差を示さなかった。各群それぞれの摂取エネルギー量及び本発明の後発酵茶の摂取量は設定通りであった。   In FIG.2 and FIG.3, there was no significant difference about the average food intake and the average water consumption of each group during the breeding period. The intake energy amount of each group and the intake amount of post-fermented tea of the present invention were as set.

各群の17週後の体重及び内臓脂肪量の体重比率を表4に示す。体重は、平均値±標準偏差で示す。平均体重相対値は、(ii)群を100として各群の相対値で示す。内臓脂肪量の体重比率は、内臓周囲脂肪、腎臓周囲脂肪、及び精巣周囲脂肪の和を内臓脂肪量とし、体重に対する比率で示す。   Table 4 shows the body weight ratios after 17 weeks of each group and the visceral fat mass. Body weight is expressed as mean ± standard deviation. The average body weight relative value is expressed as a relative value of each group with (ii) group being 100. The weight ratio of the visceral fat mass is expressed as a ratio to the body weight, with the visceral fat mass being the sum of the visceral fat, perirenal fat, and testicular fat.

Figure 2010100530
Figure 2010100530

表4では、高脂肪食投与の対照である(ii)群に対して、後発酵茶水抽出物200mg/kg(体重)/日投与の(iii)群と後発酵茶水抽出物600mg/kg(体重)/日投与の(iv)群は、いずれも高脂肪食投与による体重増加抑制及び内臓脂肪増加抑制を示した。特に、(iv)群は(ii)群と比較し、体重増加抑制及び内臓脂肪増加抑制を示し、体重及び内臓脂肪量の体重比率については、危険率1%で有意差がある事を示した。また、(iv)群の内臓脂肪量の体重比率は、普通食投与の(i)群より小さな数値を示した。後発酵茶水抽出物は、体重増加抑制及び内臓脂肪増加抑制に優れ、顕著な肥満抑制効果を示した。   In Table 4, the (iii) group of post-fermented tea water extract 200 mg / kg (body weight) / day and the post-fermented tea water extract 600 mg / kg (body weight) are compared with the group (ii) which is a high fat diet administered control. ) / Day administration group (iv) all showed suppression of weight gain and visceral fat increase by high fat diet administration. In particular, the group (iv) showed a suppression of weight gain and visceral fat increase compared to the group (ii), and the weight ratio of the body weight and the visceral fat amount showed a significant difference at a risk rate of 1%. . Moreover, the body weight ratio of the visceral fat mass of the (iv) group showed a smaller numerical value than the (i) group of the normal diet administration. The post-fermented tea water extract was excellent in suppressing weight gain and increasing visceral fat, and showed a remarkable obesity-suppressing effect.

各群の17週後における血液の生化学的検査結果を表5に示す。   Table 5 shows the blood biochemical test results after 17 weeks in each group.

Figure 2010100530
Figure 2010100530

表5では、中性脂肪と血糖値については、後発酵茶水抽出物投与の(iii)群と(iv)群は、高脂肪食投与の対照である(ii)群より小さな値を示した。コレステロールについては、(iv)群は(ii)群より小さな値を示した。
レプチンは肥満遺伝子に由来するホルモンであり血中レプチン濃度は肥満に比例して上昇する、また、アディポネクチンはホルモンであり脂肪酸の燃焼と糖の取り込みを促進しインスリン抵抗性を改善するとされている。
レプチンについては、(iii)群と(iv)群とも、(ii)群より小さな値を示した。特に、(iv)群は、(ii)群に対して有意差があることを示した。アディポネクチンについては、(iii)群と(iv)群とも、(ii)群より大きな値を示した。
従って、後発酵茶水抽出物は、血液の生化学的検査結果において顕著な肥満抑制効果を示した。
In Table 5, about the neutral fat and blood glucose level, the (iii) group and (iv) group of post-fermented tea water extract administration showed a smaller value than the (ii) group which is a control of high fat diet administration. Regarding cholesterol, the group (iv) showed a smaller value than the group (ii).
Leptin is a hormone derived from the obesity gene, and the blood leptin concentration increases in proportion to obesity, and adiponectin is a hormone that promotes fatty acid burning and sugar uptake to improve insulin resistance.
Regarding leptin, both the group (iii) and the group (iv) showed smaller values than the group (ii). In particular, the group (iv) showed a significant difference from the group (ii). As for adiponectin, both the (iii) group and the (iv) group showed larger values than the (ii) group.
Therefore, the post-fermented tea water extract showed a remarkable obesity-suppressing effect in the blood biochemical test results.

UCPについて、褐色脂肪組織中のUCPであるUCP1の発現を調べた。まず各群個々の褐色脂肪組織を摘出、次いでそれら摘出組織よりタンパク質を抽出した後、ウエスタンブロット法でUCP1及びβ−アクチンのバンドを検出し、それらバンド濃度を、数値としてデンシトメーターで読み取り、β−アクチンの数値をコントロールとして相対値として示した。数値が大きいほどUCP1量が多い。   For UCP, the expression of UCP1, a UCP in brown adipose tissue, was examined. First, each group of individual brown adipose tissues was extracted, and then proteins were extracted from the extracted tissues, UCP1 and β-actin bands were detected by Western blotting, and these band concentrations were read as numerical values with a densitometer, The value of β-actin was shown as a relative value as a control. The larger the value, the greater the amount of UCP1.

各群の17週後における褐色脂肪組織中のUCP1量を表6に示す。   Table 6 shows the amount of UCP1 in the brown adipose tissue after 17 weeks of each group.

Figure 2010100530
Figure 2010100530

表6より、UCP1の発現については、後発酵茶水抽出物投与の(iii)群と(iv)群は、高脂肪食投与の対照である(ii)群、及び普通食投与の(i)群より大であり、用量依存的にUCP1が増加し、UCP1発現促進効果を示した。従って、本発明はUCP1発現促進効果を示し、肥満抑制効果を示すものである。   From Table 6, regarding the expression of UCP1, (iii) group and (iv) group of post-fermented tea water extract administration are (ii) group which is a control of high fat diet administration, and (i) group of normal diet administration UCP1 increased in a dose-dependent manner and showed a UCP1 expression promoting effect. Therefore, the present invention shows a UCP1 expression promoting effect and an obesity suppressing effect.

各群の飼育期間中における、糞便を乾燥した後の糞便中の脂質含量を表7に示す。   Table 7 shows the lipid content in the stool after drying the stool during the breeding period of each group.

Figure 2010100530
Figure 2010100530

表7では、糞便を乾燥した後の糞便中の脂質含量は、高脂肪食投与の(ii)群、(iii)群、及び(iv)群は、普通食投与の(i)群より大きな値を示した。後発酵茶水抽出物投与の(iii)群と(iv)群は、少なくとも腸管における脂質の吸収阻害はないことを示した。   In Table 7, the fat content in the stool after drying the stool is higher in the group (ii), (iii), and (iv) of the high fat diet than in the group (i) of the normal diet showed that. Groups (iii) and (iv) of the post-fermented tea water extract administration showed that there was at least no inhibition of lipid absorption in the intestinal tract.

[製剤例1]
次の処方により、顆粒を製造した。
後発酵茶エキス末(参考例2) 350(質量部)
乳糖 470
結晶セルロース 150
ヒドロキシプロピルセルロース 30
[Formulation Example 1]
Granules were produced according to the following formulation.
Post-fermented tea extract powder (Reference Example 2) 350 (parts by mass)
Lactose 470
Crystalline cellulose 150
Hydroxypropyl cellulose 30

[製剤例2]
次の処方により、湿式造粒し、打錠して錠剤を得た。
後発酵茶エキス末(参考例2) 350(質量部)
乳糖 470
結晶セルロース 140
ヒドロキシプロピルセルロース 30
ステアリン酸マグネシウム 1
タルク 9
[Formulation Example 2]
According to the following formulation, wet granulation was performed and tablets were obtained by tableting.
Post-fermented tea extract powder (Reference Example 2) 350 (parts by mass)
Lactose 470
Crystalline cellulose 140
Hydroxypropyl cellulose 30
Magnesium stearate 1
Talc 9

各群の飼育期間中における体重変化を示す図である。It is a figure which shows the weight change during the raising period of each group. 各群の飼育期間中における摂餌量の推移を示す図である。It is a figure which shows transition of the food intake during the breeding period of each group. 各群の飼育期間中における飲水量の推移を示す図である。It is a figure which shows transition of the amount of drinking water during the breeding period of each group.

Claims (3)

Camellia sinensis種由来の茶に、茶乾燥重量100重量部に対して110重量部以上の水を加え、糸状菌を接種して生育せしめることにより得られる、スーパーオキシドジスムターゼ(Superoxide Dismutase)活性を固形分換算で2,000units/g以上を有する後発酵茶又はその抽出物を含有する抗肥満剤。   Superoxide dismutase activity obtained by adding 110 parts by weight or more of water to tea derived from Camellia sinensis seeds to 100 parts by weight of dry tea, inoculating filamentous fungi, and growing the solids. An anti-obesity agent containing post-fermented tea or an extract thereof having 2,000 units / g or more in terms of conversion. 肥満が、内臓脂肪型肥満又は皮下脂肪型肥満である請求項1記載の抗肥満剤。   The antiobesity agent according to claim 1, wherein the obesity is visceral fat type obesity or subcutaneous fat type obesity. UCPの発現を促進するものである請求項1記載の抗肥満剤。   The antiobesity agent according to claim 1, which promotes the expression of UCP.
JP2008270432A 2008-10-21 2008-10-21 Anti-obestic agent Pending JP2010100530A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008270432A JP2010100530A (en) 2008-10-21 2008-10-21 Anti-obestic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008270432A JP2010100530A (en) 2008-10-21 2008-10-21 Anti-obestic agent

Publications (1)

Publication Number Publication Date
JP2010100530A true JP2010100530A (en) 2010-05-06

Family

ID=42291516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008270432A Pending JP2010100530A (en) 2008-10-21 2008-10-21 Anti-obestic agent

Country Status (1)

Country Link
JP (1) JP2010100530A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012039889A (en) * 2010-08-12 2012-03-01 Oku Tain Fermented food using tea stem and leaf and/or sweet potato stem and leaf, and method for producing the same
ITMI20111488A1 (en) * 2011-08-03 2013-02-04 Gnosis Spa FORMULATIONS INCLUDING SACCHAROMYCES BOULARDII AND SUPEROXIDE DISMUTASIS (SOD) TO CONTROL OBESITY
WO2019131274A1 (en) * 2017-12-26 2019-07-04 国立大学法人 筑波大学 Method for producing fermentation product derived from green tea extract, and koji fermentation product derived from green tea extract
JP2020080820A (en) * 2018-11-30 2020-06-04 ユーハ味覚糖株式会社 Post-fermented tea-containing trans fatty acid selective absorption inhibitor and use thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012039889A (en) * 2010-08-12 2012-03-01 Oku Tain Fermented food using tea stem and leaf and/or sweet potato stem and leaf, and method for producing the same
ITMI20111488A1 (en) * 2011-08-03 2013-02-04 Gnosis Spa FORMULATIONS INCLUDING SACCHAROMYCES BOULARDII AND SUPEROXIDE DISMUTASIS (SOD) TO CONTROL OBESITY
WO2013017650A3 (en) * 2011-08-03 2013-04-04 Gnosis Spa Formulations comprising saccharomyces boulardii and superoxide dismutase for controlling obesity
CN103764156A (en) * 2011-08-03 2014-04-30 诺西斯有限公司 Formulations containing saccharomyces boulardii and superoxide dismutase (sod) to control obesity
KR20140051279A (en) * 2011-08-03 2014-04-30 그노시스 에스.피.에이. Formulations comprising saccharomyces boulardii and superoxide dismutase for controlling obesity
JP2014521343A (en) * 2011-08-03 2014-08-28 ニョシス ソシエタ ペル アチオニ Formulation containing Saccharomyces blaudi and superoxide dismutase (SOD) for the purpose of inhibiting obesity
RU2600843C2 (en) * 2011-08-03 2016-10-27 Ньосис Спа Compositions containing saccharomyces boulardii and superoxide dismutase (sod) for obesity control
KR101954674B1 (en) * 2011-08-03 2019-03-06 그노시스 에스.피.에이. Formulations comprising Saccharomyces boulardii and superoxide dismutase for controlling obesity
WO2019131274A1 (en) * 2017-12-26 2019-07-04 国立大学法人 筑波大学 Method for producing fermentation product derived from green tea extract, and koji fermentation product derived from green tea extract
JP2020080820A (en) * 2018-11-30 2020-06-04 ユーハ味覚糖株式会社 Post-fermented tea-containing trans fatty acid selective absorption inhibitor and use thereof

Similar Documents

Publication Publication Date Title
CN104982928B (en) A kind of japanese yew fruit health care ferment and preparation method thereof
EP1902722B1 (en) Agent for elevating adiponectin concentration
EP2271367B1 (en) Mineral absorption accelerator and iron deficiency anemia improver or food composition
KR101425466B1 (en) Leaf of Smilax china with Aspergillus species, method for preparing the same and use of the same
EP1674090A1 (en) Early insulin secretion promoter
KR20160085028A (en) Composition of EM Fermentated Puer Tea and Method of Making the Same
KR20070105486A (en) Tea and tea manufacturing method for improving liver function and curing of hangover
JP2010100530A (en) Anti-obestic agent
KR101371143B1 (en) Composition comprising chlorella for improving liver function or relieving hangover
JP4393717B2 (en) Metabolic abnormality improving method and composition therefor
JP2011020925A (en) Offal fat-type overweight inhibitor and method for producing the same
JP5794414B2 (en) Pharmaceutical composition
JP3628999B2 (en) Anonymous tea and its manufacturing method
JP2006232781A (en) Hypoglycemic composition comprising substance derived from bark of genus acacia
KR20150051597A (en) Food Composition for improving liver function containing extract of Arctiumlappa L.
KR101923603B1 (en) A composition for anti-obesity comprising green tea complex extracts
US20050137259A1 (en) Insulin secretion potentiator
JP6778506B2 (en) Functional food composition
AU2001235968A1 (en) Murraya koenigii extracts for treating asthma
EP1331939A1 (en) Murraya koenigii extracts for treating asthma
KR101399398B1 (en) Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis
JPH1149690A (en) Composition for stimulating lipolysis
JP3167777B2 (en) Antiviral, antibacterial and bactericide
KR20150073438A (en) Method for preparing fermented extract of Salvia miltiorrhiza Bunge by using of microorganism
WO2019090976A1 (en) Jerusalem artichoke capsule and preparation method therefor